How is this different from Nucala or Fasenra?

Does it really stop asthma attacks? Clinical data showed up to a 58% reduction in annual severe asthma attacks compared to standard care.

Does it really stop asthma attacks?

Will it help my sinus polyps? In April 2026, GSK is also seeking approval for nasal polyps, as IL-5 is a key driver for both conditions.

Will it help my sinus polyps?

Is it safe for my 13-year-old? Yes, it is FDA-approved for patients 12 years and older.

Is it safe for my 13-year-old?

What if I miss my 6-month shot? You should schedule your next dose as soon as possible. Because it is ultra-long-acting, you have a small “buffer,” but consistency is key for preventing flares.

What if I miss my 6-month shot?

Will insurance cover a ‘twice-yearly’ drug? Most US insurers have added Exdensur to their 2026 “Specialty Tier,” often requiring proof of an eosinophilic count (blood test).

Will insurance cover a ‘twice-yearly’ drug?

Do I still need my daily inhaler? Yes. Exdensur is an “add-on” treatment, not a replacement for your daily maintenance inhaler.

Do I still need my daily inhaler?

Can I give the shot to myself? At the 2026 launch, it is primarily clinic-administered, though an “at-home” autoinjector may be released later.

Can I give the shot to myself?

How do I know if I have ‘Eosinophilic’ asthma? Your doctor can confirm this with a simple blood test looking for a specific type of white blood cell (eosinophils).

How do I know if I have ‘Eosinophilic’ asthma?

Is there a co-pay assistance program? Yes, the “Exdensur Access” program launched in April 2026 to help eligible US patients with commercial insurance.

May 2026 - Exdensur (depemokimab-ulaa)

Introduction

Exdensur (depemokimab-ulaa) is the first ultra-long-acting biologic approved by the FDA in April 2026 as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype. It is a humanized monoclonal antibody designed to inhibit interleukin-5 (IL-5), the primary protein responsible for the inflammation seen in severe asthma. In the US, Exdensur is a game-changer because its extended half-life allows for a 6-month dosing interval, providing continuous protection against life-threatening asthma attacks with significantly fewer clinic visits.

Usage and Indications

In the US, Exdensur is FDA-approved for:

Severe Eosinophilic Asthma: As an add-on maintenance treatment for adults and pediatric patients aged 12 years and older.
It is specifically for patients whose asthma is not well-controlled by high-dose inhaled corticosteroids plus an additional maintenance medication.
Note: It is not used to treat sudden breathing problems (rescue) and should not be used for acute bronchospasm.

How to Take It (Dosage)

Form: Subcutaneous injection.
Frequency: Once every 6 months (26 weeks).
Administration: In the 2026 US rollout, Exdensur is typically administered by a healthcare professional in a clinic setting.
Dose: A fixed dose regardless of body weight for patients over 12 years old.

Side Effects

Clinical trials (SWIFT-1 and SWIFT-2) showed a safety profile comparable to placebo:

Common: Nasopharyngitis (common cold symptoms), headache, and injection site reactions (redness or swelling).
Moderate: Back pain and upper respiratory tract infections.
Serious (Rare): Hypersensitivity reactions (anaphylaxis) can occur. Patients are typically monitored for a short period after the injection.

Precautions and Warnings

Not for Acute Symptoms: Do not use Exdensur to treat an asthma attack. Always keep a rescue inhaler (like Albuterol) on hand.
Corticosteroid Reduction: Do not abruptly stop taking your inhaled steroids when starting Exdensur. Any reduction in steroid dose must be gradual and supervised by a doctor.
Parasitic Infections: IL-5 is involved in the body’s response to certain parasite infections. If you have a pre-existing parasitic infection, it should be treated before starting Exdensur.

Interactions

Other Biologics: Exdensur should not be used in combination with other IL-5 inhibitors (like Nucala, Fasenra, or Cinqair).
Vaccines: In 2026, US guidelines suggest that most non-live vaccines can be taken, but you should discuss the timing of any “live” vaccines with your specialist.

Storage

Refrigeration: Must be stored in a refrigerator (36°F to 46°F).
Light Protection: Keep in the original carton until the time of administration.

FAQ

How is this different from Nucala or Fasenra? While those work similarly, they require injections every 4 to 8 weeks. Exdensur lasts for 6 months per dose.
Does it really stop asthma attacks? Clinical data showed up to a 58% reduction in annual severe asthma attacks compared to standard care.
Will it help my sinus polyps? In April 2026, GSK is also seeking approval for nasal polyps, as IL-5 is a key driver for both conditions.
Is it safe for my 13-year-old? Yes, it is FDA-approved for patients 12 years and older.
What if I miss my 6-month shot? You should schedule your next dose as soon as possible. Because it is ultra-long-acting, you have a small “buffer,” but consistency is key for preventing flares.
Will insurance cover a ‘twice-yearly’ drug? Most US insurers have added Exdensur to their 2026 “Specialty Tier,” often requiring proof of an eosinophilic count (blood test).
Do I still need my daily inhaler? Yes. Exdensur is an “add-on” treatment, not a replacement for your daily maintenance inhaler.
Can I give the shot to myself? At the 2026 launch, it is primarily clinic-administered, though an “at-home” autoinjector may be released later.
How do I know if I have ‘Eosinophilic’ asthma? Your doctor can confirm this with a simple blood test looking for a specific type of white blood cell (eosinophils).
Is there a co-pay assistance program? Yes, the “Exdensur Access” program launched in April 2026 to help eligible US patients with commercial insurance.